Krintafel Generic Name & Formulations
Tafenoquine 150mg; tabs.
Prevention of P. vivax malaria relapse in patients who are receiving chloroquine therapy for acute P. vivax infection.
Limitations of Use
Not for treatment of acute P. vivax malaria.
Krintafel Dosage and Administration
Swallow whole. Take with food. ≥16yrs: 300mg (2 tabs) as a single dose on the first or second day of chloroquine therapy.
<16yrs: not established.
G6PD deficiency or unknown status. Nursing mothers when infant is G6PD deficient or status unknown.
Krintafel Boxed Warnings
Must test for G6PD deficiency prior to initiation. Monitor for hemolysis; treat if occurs. NADH-dependent methemoglobin reductase deficiency; monitor. History of psychiatric illness; evaluate benefits vs risks. Discontinue and treat if hypersensitivity reactions occur. Renal or hepatic impairment: monitor. Exclude pregnancy status prior to initiation. Pregnancy: not recommended. Advise females of reproductive potential to use effective contraception during and for 3 months after dose. Nursing mothers: not recommended (during and for 3 months after dose) in G6PD-deficient infant or status unknown.
Concomitant other antimalarials (other than chloroquine): not recommended. Avoid concomitant OCT2 and MATE substrates (eg, dofetilide, metformin); if unavoidable, monitor and consider dose reduction of substrate if needed.
Krintafel Adverse Reactions
Dizziness, nausea, vomiting, headache, decreased hemoglobin; hemolytic anemia, methemoglobinemia, psychiatric effects, hypersensitivity reactions.
Krintafel Clinical Trials
Krintafel Patient Counseling